Date of announcement  2020/07/27
Time of announcement  18:01:04
 
Date of events   2020/07/27 
To which item it meets paragraph 20
Statement 
1.Name and nature of the underlying assets (if preferred shares, the terms
and conditions of issuance shall also be indicated, e.g., dividend yield,
etc.):Partnership interest of Healthcare
Fund II(tentative name)
2.Date of occurrence of the event:2020/07/27
3.Amount, unit price, and total monetary amount of the transaction:
(1)Volume and unit price: N/A
(2)Total monetary amount: Up to NT$ 1,035 million
or 32.33% of fund size, whichever is lower.
4.Trading counterparty and its relationship with the Company (if the trading
counterparty is a natural person and furthermore is not a related party of
the Company, the name of the trading counterparty is not required to be
disclosed):Counterpart：Healthcare Fund II
Its relationship to the Company：Related party disclosed
in financial statements upon its establishment.
5.Where the trading counterparty is a related party, announcement shall also
be made of the reason for choosing the related party as trading counterparty
and the identity of the previous owner, its relationship with the Company
and the trading counterparty, and the previous date and monetary amount of
transfer:Healthcare Fund II is a new fund raised by the
Group; No previous transfer.
6.Where an owner of the underlying assets within the past five years has
been a related party of the Company, the announcement shall also include the
date and price of acquisition and disposal by the related party, and its
relationship with the Company at the time of the transaction:N/A
7.Matters related to the current disposal of creditors' rights (including
types of collaterals of the disposed creditor’s rights; if creditor's
rights over a related party, announcement shall be made of the name of the
related party and the book amount of the creditor's rights, currently being
disposed of, over such related party):N/A
8.Profit or loss from the disposal (not applicable in cases of acquisition
of securities) (those with deferral should provide a table explaining
recognition):N/A
9.Terms of delivery or payment (including payment period and monetary
amount), restrictive covenants in the contract, and other important terms
and conditions:According to the agreement
among all investors.
10.The manner of deciding on this transaction (such as invitation to tender,
price comparison, or price negotiation), the reference basis for the
decision on price, and the decision-making unit:
The manner in which the current transaction was decided,
the reference basis for the decision on price：
To subscribe for limited partnership interests
The decision-making department：the Board of Directors
11.Net worth per share of the Company's underlying securities acquired or
disposed of:N/A
12.Cumulative no.of shares held (including the current transaction), their
monetary amount, shareholding percentage, and status of any restriction of
rights (e.g., pledges), as of the present moment:
Cumulative volume：N/A
Cumulative amount：Up to NT$ 1,035 million.
Shareholding percentage： Not exceeding 32.33%
Status of any restriction of rights：N/A
13.Current ratio of securities investment (including the current trade, as
listed in article 3 of Regulations Governing the Acquisition and Disposal of
Assets by Public Companies) to the total assets and equity attributable to
owners of the parent as shown in the most recent financial statement and
working capital as shown in the most recent financial statement as of the
present:
Current ratio of long or short term securities investment
(including the current trade) to the total assets in the
most recent financial statement：18.22%
Current ratio of long or short term securities investment
(including the current trade) to the shareholder's equity
in the most recent financial statement：19.34%
The working capital as shown in the most recent financial
statement：NT$12,286,056 thousand
14.Broker and broker's fee:N/A
15.Concrete purpose or use of the acquisition or disposal:
For the needs of investment portfolio  expansion
16.Any dissenting opinions of directors to the present transaction:
NO
17.Whether the counterparty of the current transaction is
a related party:Yes
18.Date of the board of directors resolution:2020/07/27
19.Date of ratification by supervisors or approval by
the Audit Committee:NA
20.Whether the CPA issued an unreasonable opinion regarding the current
transaction:N/A
21.Name of the CPA firm:N/A
22.Name of the CPA:N/A
23.Practice certificate number of the CPA:N/A
24.Whether the transaction involved in change of business model:NO
25.Details on change of business model:N/A
26.Details on transactions with the counterparty for the past year and the
expected coming year:
Since Healthcare Fund II is a new fund raised by the Group,
there was no prior transaction. Healthcare Fund II will
invest in Healthcare industry.
27.Source of funds:CDIB Venture Capital Corporation' own funds.
28.Any other matters that need to be specified:None.